cbdMD Stock Forecast, Price & News

-0.04 (-1.64 %)
(As of 08/4/2021 10:18 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume25 shs
Average Volume163,055 shs
Market Capitalization$135.41 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive YCBD News and Ratings via Email

Sign-up to receive the latest news and ratings for cbdMD and its competitors with MarketBeat's FREE daily newsletter.

cbdMD logo

About cbdMD

cbdMD, Inc. produces and distributes various cannabidiol (CBD) products. It owns and operates consumer hemp-based CBD brands, such as cbdMD and Paw CBD. Its cbdMD brand products include CDB tinctures, gummies, topicals, capsules, bath bombs, bath salts, and sleep aids. The company also offers veterinarian-formulated products, including tinctures, chews, and topicals under the Paw CBD brand name. It distributes its products through its e-commerce Website, third party e-commerce sites, wholesalers, and various brick and mortar retailers in the United States. The company was formerly known as Level Brands, Inc. and changed its name to cbdMD, Inc. in May 2019. cbdMD, Inc. was founded in 2015 and is headquartered in Charlotte, North Carolina.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.71 out of 5 stars

Analyst Opinion: 3.0Community Rank: 3.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

cbdMD (NYSEAMERICAN:YCBD) Frequently Asked Questions

Is cbdMD a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for cbdMD in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" cbdMD stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in YCBD, but not buy additional shares or sell existing shares.
View analyst ratings for cbdMD
or view top-rated stocks.

What stocks does MarketBeat like better than cbdMD?

Wall Street analysts have given cbdMD a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but cbdMD wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting cbdMD?

cbdMD saw a drop in short interest during the month of June. As of June 30th, there was short interest totaling 8,300 shares, a drop of 99.5% from the June 15th total of 1,660,000 shares. Based on an average daily trading volume, of 281,500 shares, the short-interest ratio is currently 0.0 days. Currently, 0.0% of the shares of the company are short sold.
View cbdMD's Short Interest

When is cbdMD's next earnings date?

cbdMD is scheduled to release its next quarterly earnings announcement on Wednesday, August 11th 2021.
View our earnings forecast for cbdMD

How were cbdMD's earnings last quarter?

cbdMD, Inc. (NYSEAMERICAN:YCBD) announced its quarterly earnings data on Wednesday, May, 12th. The company reported ($0.24) EPS for the quarter, missing the Zacks' consensus estimate of ($0.03) by $0.21. The business earned $11.80 million during the quarter. cbdMD had a negative trailing twelve-month return on equity of 35.34% and a negative net margin of 79.89%.
View cbdMD's earnings history

How has cbdMD's stock price been impacted by COVID-19?

cbdMD's stock was trading at $0.82 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, YCBD shares have increased by 195.1% and is now trading at $2.42.
View which stocks have been most impacted by COVID-19

What guidance has cbdMD issued on next quarter's earnings?

cbdMD issued an update on its first quarter 2022 earnings guidance on Tuesday, June, 8th. The company provided earnings per share guidance of $- for the period. The company issued revenue guidance of $15.50 million-16.25 million.

What price target have analysts set for YCBD?

2 analysts have issued twelve-month price objectives for cbdMD's stock. Their forecasts range from $3.25 to $4.00. On average, they anticipate cbdMD's share price to reach $3.63 in the next twelve months. This suggests a possible upside of 49.8% from the stock's current price.
View analysts' price targets for cbdMD
or view top-rated stocks among Wall Street analysts.

Who are cbdMD's key executives?

cbdMD's management team includes the following people:
  • Mr. Martin A. Sumichrast, Chairman & Co-CEO (Age 54, Pay $441k)
  • Mr. Raymond Scott Coffman, Co-Founder, Pres, Co-CEO & Director (Age 59, Pay $186.92k)
  • Mr. T. Ronan Kennedy, CFO, COO, Sec. & Treasurer (Age 41)
  • Mr. John Weston, Director of Investor Relations
  • Mr. Lance Blundell, Gen. Counsel
  • Mr. Ken Cohn, Chief Marketing Officer
  • Mr. Francisco Mangual, Sr. VP of Sales

Who are some of cbdMD's key competitors?

What other stocks do shareholders of cbdMD own?

What is cbdMD's stock symbol?

cbdMD trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "YCBD."

Who are cbdMD's major shareholders?

cbdMD's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Davy Global Fund Management Ltd (0.38%) and Cutler Group LP (0.00%). Company insiders that own cbdMD stock include Bakari T Sellers, Mark S Elliott, Martin A Sumichrast, Peter J Ghiloni, Raymond Scott Coffman and William F Raines III.
View institutional ownership trends for cbdMD

Which institutional investors are selling cbdMD stock?

YCBD stock was sold by a variety of institutional investors in the last quarter, including Cutler Group LP. Company insiders that have sold cbdMD company stock in the last year include Bakari T Sellers, Martin A Sumichrast, Raymond Scott Coffman, and William F Raines III.
View insider buying and selling activity for cbdMD
or view top insider-selling stocks.

Which institutional investors are buying cbdMD stock?

YCBD stock was acquired by a variety of institutional investors in the last quarter, including Davy Global Fund Management Ltd. Company insiders that have bought cbdMD stock in the last two years include Bakari T Sellers, Mark S Elliott, Peter J Ghiloni, and Raymond Scott Coffman.
View insider buying and selling activity for cbdMD
or or view top insider-buying stocks.

How do I buy shares of cbdMD?

Shares of YCBD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is cbdMD's stock price today?

One share of YCBD stock can currently be purchased for approximately $2.42.

How much money does cbdMD make?

cbdMD has a market capitalization of $136.54 million and generates $41.88 million in revenue each year. The company earns $12.60 million in net income (profit) each year or $0.28 on an earnings per share basis.

How many employees does cbdMD have?

cbdMD employs 165 workers across the globe.

What is cbdMD's official website?

The official website for cbdMD is www.cbdmd.com.

Where are cbdMD's headquarters?

cbdMD is headquartered at 8845 Red Oak Boulevard, Charlotte NC, 28217.

How can I contact cbdMD?

cbdMD's mailing address is 8845 Red Oak Boulevard, Charlotte NC, 28217. The company can be reached via phone at 704-445-5800 or via email at [email protected]

This page was last updated on 8/4/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.